Amanda W. Lund

Amanda W. Lund

Auto-generated profile, based on publicly available information

Amanda W. Lund

Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Cell
Verified
Journal Article
Closed access
FRFlorian Rambow
Florian Rambow
ARAljosja Rogiers
Aljosja Rogiers
OMOskar Marin-Bejar
Oskar Marin-Bejar
SASara Aibar
Sara Aibar
JFJulia Femel
Julia Femel
JMJean-Christophe Marine
Jean-Christophe Marine

24 February 2012 in Nature Reviews Cancer
Verified
Journal Article
Closed access
MSMelody A. Swartz
Melody A. Swartz
ALAmanda W. Lund
Amanda W. Lund

3 September 2021 in Science Immunology
Verified
Journal Article
Closed access
HBHaley du Bois
Haley du Bois
THTaylor A. Heim
Taylor A. Heim
ALAmanda W. Lund
Amanda W. Lund
Tumors remodel their draining lymph nodes to simultaneously affect both metastatic potential and systemic immune surveillance.

1 March 2012 in Cell Reports
Verified
Journal Article
Open access
ALAmanda W. Lund
Amanda W. Lund
FDFernanda V. Duraes
Fernanda V. Duraes
SHSachiko Hirosue
Sachiko Hirosue
VRVidya R. Raghavan
Vidya R. Raghavan
CNChiara Nembrini
Chiara Nembrini
MSMelody A. Swartz
Melody A. Swartz
Tumor expression of the lymphangiogenic factor VEGF-C is correlated with metastasis and poor prognosis, and although VEGF-C enhances transport to the draining lymph node (dLN) and antigen exposure to the adaptive immune system, its role in tumor immunity remains unexplored. Here, we demonstrate that VEGF-C promotes immune tolerance in murine melanoma. In B16 F10 melanomas expressing a foreign antigen (OVA), VEGF-C protected tumors against preexisting antitumor immunity and promoted local deletion of OVA-specific CD8(+) T cells. Naive OVA-specific CD8(+) T cells, transferred into tumor-bearing mice, were dysfunctionally activated and apoptotic. Lymphatic endothelial cells (LECs) in dLNs cross-presented OVA, and naive LECs scavenge and cross-present OVA in vitro. Cross-presenting LECs drove the proliferation and apoptosis of OVA-specific CD8(+) T cells ex vivo. Our findings introduce a tumor-promoting role for lymphatics in the tumor and dLN and suggest that lymphatic endothelium in the local microenvironment may be a target for immunomodulation.

13 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
GWGregor Werba
Gregor Werba
DWDaniel Weissinger
Daniel Weissinger
EKEmily A. Kawaler
Emily A. Kawaler
EZEnde Zhao
Ende Zhao
DKDespoina Kalfakakou
Despoina Kalfakakou
DSDiane M. Simeone
Diane M. Simeone
The tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDAC) is a complex ecosystem that drives tumor progression; however, in-depth single cell characterization of the PDAC TME and its role in response to therapy is lacking. Here, we perform single-cell RNA sequencing on freshly collected human PDAC samples either before or after chemotherapy. Overall, we find a heterogeneous mixture of basal and classical cancer cell subtypes, along with distinct cancer-associated fibroblast and macrophage subpopulations. Strikingly, classical and basal-like cancer cells exhibit similar transcriptional responses to chemotherapy and do not demonstrate a shift towards a basal-like transcriptional program among treated samples. We observe decreased ligand-receptor interactions in treated samples, particularly between TIGIT on CD8 + T cells and its receptor on cancer cells, and identify TIGIT as the major inhibitory checkpoint molecule of CD8 + T cells. Our results suggest that chemotherapy profoundly impacts the PDAC TME and may promote resistance to immunotherapy.

1 January 2014 in Biomaterials
Verified
Journal Article
Open access
STSusan N. Thomas
Susan N. Thomas
EVEfthymia Vokali
Efthymia Vokali
ALAmanda W. Lund
Amanda W. Lund
JHJeffrey A. Hubbell
Jeffrey A. Hubbell
MSMelody A. Swartz
Melody A. Swartz
Accumulating evidence implicates the tumor-draining lymph node (TDLN) in tumor-induced immune escape, as it drains regulatory molecules and leukocytes from the tumor microenvironment. We asked whether targeted delivery of adjuvant to the TDLN, presumably already bathed in tumor antigens, could promote anti-tumor immunity and hinder tumor growth. To this end, we used 30 nm polymeric nanoparticles (NPs) that effectively target dendritic cells (DCs, CD11c(+)) within the lymph node (LN) after intradermal administration. These NPs accumulated within the TDLN when administered in the limb ipsilateral (i.l.) to the tumor or in the non-TDLN when administered in the contralateral (c.l.) limb. Incorporating the adjuvants CpG or paclitaxel into the NPs (CpG-NP and PXL-NP) induced DC maturation in vitro. When administered daily i.l. and thus targeting the TDLN of a B16-F10 melanoma, adjuvanted NPs induced DC maturation within the TDLN and reshaped the CD4(+) T cell distribution within the tumor towards a Th1 (CXCR3(+)) phenotype. Importantly, this also led to an increase in the frequency of antigen-specific CD8(+) T cells within the tumor. This correlated with slowed tumor growth, in contrast to unhindered tumor growth after c.l. delivery of adjuvanted NPs (targeting a non-TDLN) or i.l. delivery of free adjuvant. CpG-NP treatment in the i.l. limb also was associated with an increase in CD8(+)/CD4(+) T cell ratios and frequencies of activated (CD25(+)) CD8(+) T cells within the TDLN whereas PXL-NP treatment reduced the frequency of regulatory T (FoxP3(+) CD4(+)) cells in the TDLN. Together, these data implicate the TDLN as a delivery target for adjuvant therapy of solid tumors.